Clinical Characteristics of the Mumbai HIV/MDR-TB co-infected adolescent cohort, 2007–2013.

<p>M: male; F: female; D4T: stavudine; 3TC: lamivudine; EFV: efavirenz; TDF: tenofovir; AZT: zidovudine; ABC: abacavir; NVP: nevirapine; ATV/r: atazanavir/ritonavir; LPV: lopinavir; PTB: pulmonary tuberculosis; EPTB: extra-pulmonary tuberculosis; Abd; abdominal; Cereb; cerebral, LN: lymph node; NEG: negative; POS: positive; S: streptomycin; Cm: capreomycin; Km: kanamycin; Lfx: levofloxacin; Eto: ethionamide; CS: cycloserine; Amcl: amoxicillin/clavulanic acid; Mfx: moxifloxacin; Ofx; ofloxacin; PAS; para-aminosalicylic acid; Z: pyrazinamide; H: isoniazid; Hh: high dose isoniazid; E: ethambutol; Cfz: clofazimine; XDR: extensively drug-resistant; MDR: multidrug-resistant.</p>*<p>at time of MDR-TB diagnosis.</p

Xpert testing strategies and MTB detection.

<p>Xpert testing strategies and MTB detection.</p

Flowchart of the Mumbai HIV/MDR-TB co-infected adolescent cohort, 2007–2013.

<p>Flowchart of the Mumbai HIV/MDR-TB co-infected adolescent cohort, 2007–2013.</p

Outcomes of the Mumbai HIV/MDR-TB co-infected adolescent cohort, 2007–2013.

<p>Outcomes of the Mumbai HIV/MDR-TB co-infected adolescent cohort, 2007–2013.</p

Treatment-related adverse events in the Mumbai HIV/MDR-TB co-infected adolescent cohort, 2007–2013.

<p>M: male; F: female; S: streptomycin; Cm: capreomycin; Km: kanamycin; Lfx: levofloxacin; Eto: ethionamide; CS: cycloserine; Amcl: amoxicillin/clavulanic acid; Mfx: moxifloxacin; PAS: para-aminosalicylic acid; Z: pyrazinamide; H: isoniazid; Hh: high dose isoniazid; E; ethambutol, Cfz: clofazimine; GI: gastrointestinal; CrCl: creatinine clearanc.</p

Demographic and clinical characteristics of patients receiving self-administered tuberculosis treatment (SAT) in Mon district, Nagaland, India, 2012–2013.

<p>Demographic and clinical characteristics of patients receiving self-administered tuberculosis treatment (SAT) in Mon district, Nagaland, India, 2012–2013.</p

Demographic and clinical characteristics of ‘Semi-urban’ and ‘Rural’ patients receiving self-administered tuberculosis treatment (SAT) in Mon district, Nagaland, India, 2012–2013.

<p>IQR: Interquartile range.</p><p>Demographic and clinical characteristics of ‘Semi-urban’ and ‘Rural’ patients receiving self-administered tuberculosis treatment (SAT) in Mon district, Nagaland, India, 2012–2013.</p

Demographic and clinical factors associated with unsuccessful treatment outcomes among patients receiving self-administered TB treatment (SAT) in Mon district, Nagaland, India, 2012–2013.

†<p>Row percentage in parenthesis.</p><p>IQR: Inter-quartile range.</p>a<p>aOR: adjusted Odds Ratios (calculated by binary logistic regression).</p><p>Demographic and clinical factors associated with unsuccessful treatment outcomes among patients receiving self-administered TB treatment (SAT) in Mon district, Nagaland, India, 2012–2013.</p

HIV/MDR-TB co-infected patients who developed hypothyroidism during the study period.

<p>HIV/MDR-TB co-infected patients who developed hypothyroidism during the study period.</p

Resistance profile (first and second-line anti-TB drugs) for MDR-TB patients in greater metropolitan Mumbai, 2005–2013.

<p>S-streptomycin, H-isoniazid, R-rifampicin, E-ethambutol, Z- Pyrazinamide, Ofx-ofloxacin, Mfx-Moxifloxacin, Km-kanamycin, Am-Amikacin, Cm-capreomycin, Eto-ethionamide, Cfz- Clofazimine, PAS- para-aminosalicylic acid</p><p>*Linear-by-linear association chi-square test, p value<0.05.</p><p>Resistance profile (first and second-line anti-TB drugs) for MDR-TB patients in greater metropolitan Mumbai, 2005–2013.</p